Hikma Pharmaceuticals non-exec sells 5,700 shares

Ronald Goode, a non-Executive Director of Hikma Pharmaceuticals, has disposed of 5,700 shares at 983.00p each.The £56,031 sale comes less than a week after the company upgraded its 2013 revenue growth forecast following a strong start to the year. In an announcment released May 16th, the group told investors it expects revenue to rise 13% this year, up from its previous guidance of 10%, driven by the performance of Branded and Injectables and Generics businesses in the year-to-date. The Branded and Injectables unit is on track to meet the firm's full-year guidance, while the Generics arm is continuing to benefit from its doxycycline product which is delivering revenue ahead of forecasts. Branded revenue is expected to increase 11% in 2013, with a slight improvement in adjusted operating margin. Goode now owns 17,000 shares. Top Director BuysSymphony International Holdings Ltd. (SIHL) Amount purchased: 500,000 @ $0.78 Director name: Mr Anil ThadaniValue: $388,750Symphony International Holdings Ltd. (SIHL) Director name: Mr Anil ThadaniAmount purchased: 30,000 @ $0.76 Value: $22,800Xchanging (XCH) Director name: Mr Bill ThomasAmount purchased: 14,289 @ 139.97p Value: £20,000Zotefoams (ZTF) Director name: Ms Marie-Louise Clayton Amount purchased: 8,000 @ 195.00p Value: £15,600JPMorgan Overseas Inv Trust (JMO) Director name: Mr Jonathan Carey Amount purchased: 1,500 @ 923.00p Value: £13,845JPMorgan Claverhouse Inv Trust (JCH) Director name: Mr Andrew L SutchAmount purchased: 2,196 @ 521.39p Value: £11,450Top Director SellsSirius Minerals (SXX) Director name: Mr Jason MurrayAmount sold: 2,166,667 @ 23.00p Value: £498,333Spectris (SXS) Director name: Mr James WebsterAmount sold: 19,821 @ 2,129.31p Value: £422,051Hikma Pharmaceuticals (HIK) Director name: Dr Ronald GoodeAmount sold: 5,700 @ 983.00p Value: £56,031NR